... San Antonio Breast Cancer Symposium on Wednesday. Already registered ... Krystal Biotech Expects CHMP Opinion on Skin Condition Gene Therapy in Early ...
News
- Eli Lilly's SERD Benefits Endocrine-Resistant Breast Cancer Patients as Single-Agent, Combination
- Kazia Therapeutics to Present Data Highlighting Synergistic Activity Between Paxalisib and ...
... San Antonio Breast Cancer Symposium highlighting the activity the ... Sarepta, Biotech's Regulatory Go-Getter, Signs Standout Rare Disease Deal.
- Celcuity's Breast Cancer Drug Shows Breakthrough 77-Month Survival Data in Clinical Trial
The data was presented at the San Antonio Breast Cancer Symposium (SABCS) in December 2024. ... Celcuity is a clinical-stage biotechnology ...
- Celcuity Presents Overall Survival Data from Phase 1b Study Evaluating Gedatolisib in ...
... San Antonio Breast Cancer Symposium. Celcuity Presents Overall Survival ... Celcuity is a clinical-stage biotechnology company focused on ...
- Houston Medicine Magazine Headlines Powered By Business Wire
Health | Biotechnology | Pharmaceutical ... BostonGene Unveils Transformative Breast Cancer Research at 2024 San Antonio Breast Cancer Symposium, ...